S. Vincent Rajkumar

ORCID iD
https://orcid.org/0000-0002-5862-1833
  • Country
  • Show details Hide details
United States

Sources:
S. Vincent Rajkumar (2016-01-24)

  • Keywords
  • Show details Hide details
cancer, myeloma, monoclonal gammopathy, therapy, clinical trials

Sources:
S. Vincent Rajkumar (2014-01-27)

  • Other IDs
  • Show details Hide details
Scopus Author ID: 7007085917

Sources:
Scopus - Elsevier (2014-01-28)

Biography

Dr. S. Vincent Rajkumar is Edward W. and Betty Knight Scripps Professor of Medicine at the Mayo Clinic, Rochester, Minnesota. He is internationally recognized as a leading expert in the field of multiple myeloma and related plasma cell disorders. Dr. Rajkumar completed his medical education at the Christian Medical College, Vellore, India. His journey from India to the United States and his present career was profiled in the Lancet in 2011 (doi:10.1016/S0140-6736(11)61801-1). From 1992-1995, he served as a resident in internal medicine at the University of North Dakota School of Medicine, Fargo, North Dakota. He then completed subspecialty training in hematology and medical oncology at the Mayo Graduate School of Medicine. He was appointed to the Mayo Clinic faculty in 1999. Dr. Rajkumar is presently Chair of the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group. He also chairs the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee. Dr. Rajkumar has a multi-faceted research program in the field of plasma cell disorders involving clinical trials, epidemiologic studies, and laboratory research. He has led numerous phase I, II, and III clinical trials investigating the role of new agents in myeloma, including the pivotal trials that led to the approval of thalidomide in myeloma in the United States. As chair of the ECOG myeloma committee he leads the design and implementation of several national phase III randomized trials for the disease. Dr. Rajkumar also leads several large epidemiological studies investigating the epidemiology, prevalence, and progression of various monoclonal gammopathies including myeloma. His current laboratory research is focused on investigating novel agents in myeloma, and studying the role of angiogenesis in various plasma cell disorders. His research is primarily funded by the US National Institutes of Health. He has published more than 300 peer-reviewed papers primarily in the field of myeloma and related plasma cell disorders. Dr. Rajkumar is Associate Editor for the Mayo Clinic Proceedings; Section Editor for multiple myeloma and related disorders for the journal Leukemia; Associate Editor for the European Journal of Haematology; and Editor-in-Chief of Blood Cancer Journal.

Record last modified {{lastModifiedDate}}